This article is more than 5 years old. Information may no longer be current.
Omeros reports positive data on drug product candidate
Click Here to Manage Email Alerts
SEATTLE — Omeros has announced that OMS302, its proprietary product candidate under development for use in ophthalmological procedures, had positive data reports from a phase 2b clinical trial in patients undergoing cataract surgery, according to a company press release.
OMS302 maintains intraoperative mydriasis and reduces postoperative pain and irritation resulting from cataract and other lens replacement surgery, the release said.
The multicenter, double-blind, vehicle-controlled trial included 221 patients randomized into four parallel treatment groups. Subjects treated with OMS302 demonstrated statistically significant maintenance of pupil dilation throughout the cataract procedure (P < .0001). OMS302 also significantly decreased pain in the early postoperative period (P = .0418) and reduced the frequency of complaints of moderate and severe pain, according to the release.
"Because OMS302 is administered through the irrigation solution currently used during lens exchange, the drug product fits readily into the workflow of the operating room and does not require a change in the surgeon's routine procedure," Mark I. Rosenblatt, MD, PhD, associate professor of ophthalmology at Weill Cornell Medical College, said in the release.
OMS302 was safe and well tolerated in the study.